Pediatric Congenital Adrenal Hyperplasia Management: Regret and Long-term Outcomes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-65
SponsorUniversity Hospital, Lille

About this trial

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a chronic endocrine disorder, often diagnosed in the neonatal period. Severe forms may lead to genital virilization in afected girls and adrenal crises. Management includes lifelong hormone replacement therapy and, historically, early genital surgery, although recent guidelines recommend delaying non-urgent procedures to preserve patient autonomy.This study hypothesizes that pediatric management, particularly early surgical interventions, may influence long-term satisfaction and the expression of regret in adulthood. We will conduct an observational cross-sectional study including adult patients diagnosed with CAH during childhood. Data will be collected using standardized questionnaires assessing medical regret, quality of life, sexual function, and psychological outcomes, together with clinical characteristics and past medical and surgical history.The primary outcome is the prevalence of regret related to pediatric care. Secondary outcomes include quality of life, sexual satisfaction, psychological status, and adaptation of hormonal therapy from adolescence to adulthood. Patient-reported outcomes (regret, quality of life, sexual function, and psychological outcomes) will be assessed in female participants only, male participants will be included for the evaluation of hormonal treatment adaptation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients aged 18 years or older

Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Followed at Lille University Hospital

Able to understand the study information and complete the questionnaires in French

Disqualifiers

Patients younger than 18 years

Non-classic forms of congenital adrenal hyperplasia

Inability to understand the study information or to complete the questionnaires

Refusal to participate or lack of informed consent

Trial population

Patients with classic congenital adrenal hyperplasia (CAH) followed in the departments of gynecology, endocrinology, and pediatrics at Lille University Hospital, France.

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

  • questionnaire

    Other intervention

    Standardized questionnaires assessing regret related to pediatric management, quality of life, sexual function, and psychological outcomes.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Regret related to pediatric management

Regret related to pediatric management assessed by the Decision Regret Scale (DRS)

Time frame
At study inclusion (baseline)

Secondary outcomes

1

Quality of life

Quality of life assessed by the WHOQOL-BREF questionnaire

Time frame
at study inclusion (baseline)
2

Sexual function

Sexual function assessed by the Arizona Sexual Experience Scale (ASEX)

Time frame
at study inclusion (baseline)
3

Symptoms of anxiety and depression

Symptoms of anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS)

Time frame
at study inclusion
4

Adaptation of hormonal treatment from adolescence to adulthood

Adaptation of hormonal treatments from adolescence to adulthood, assessed from medical history

Time frame
at study inclusion (baseline)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.